ClinicalTrials.Veeva

Menu

Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging

F

Far Eastern Memorial Hospital

Status

Unknown

Conditions

Hypertrophic Cardiomyopathy
Myocardial Perfusion Imaging

Treatments

Diagnostic Test: myocardial perfusion imaging

Study type

Observational

Funder types

Other

Identifiers

NCT03150342
106057-E

Details and patient eligibility

About

Chest pain and myocardial ischemia are prevailing features in patients with hypertrophic cardiomyopathy (HCM). Recently introduced single-photon emission computed tomography (SPECT) cameras with solid-state cadmium-zinc-telluride (CZT) detectors have been shown to decrease imaging time and improved the imaging quality of gated myocardial perfusion imaging (MPI). The investigators also correlate the MPI parameters with echocardiographic parameters. This study is to examine the spatial distribution of stress perfusion abnormalities and tissue injury in patients with HCM using a CZT SPECT camera.

Full description

The investigators will retrospectively evaluate myocardial perfusion patterns and cardiac function with Thallium (Tl)-201 gated dipyridamole MPI in patients with clinical diagnosis of HCM and patent coronary angiography between January 2013 and October 2016. The inclusion criteria included a spade-like configuration on left ventriculogram, or echocardiographic findings suggestive of HCM. The participants will be then divided into the following three groups: apical, concentric and septal forms. Regional perfusion would be analyzed using a 17-segment model from 0-4 degree (0=normal, to 4=absent perfusion); and summed stress score (SSS), summed rest score (SRS) and summed difference score (SDS) were calculated. Gated SPECT would be processed by quantitative gated SPECT (QGS) software (Cedars-Sinai Medical Center, Los Angeles, CA, USA) and ejection fraction phase analysis. Diastolic parameters would be also acquired by Doppler echocardiography, and correlated with MPI parameters.

Enrollment

100 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • clinical diagnosis of HCM and patent coronary angiography between January 2013 and October 2016.

Exclusion criteria

  • patient with prior myocardial ischemia, conduction abnormality, valvular disease or other cardiomyopathy

Trial contacts and locations

1

Loading...

Central trial contact

Szu-Ying Tsai, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems